Trials / Completed
CompletedNCT03251443
A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
Single Center, Single Arm, Open Study, to Explore and Evaluate Treatment of Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore the efficacy and safety of second-line treatment of apatinib in advanced intrahepatic cholangiocarcinoma patients and evaluate drug safety, progression free and overall survival. The primary endpoint of this study is objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops. |
Timeline
- Start date
- 2017-08-08
- Primary completion
- 2019-03-08
- Completion
- 2019-05-08
- First posted
- 2017-08-16
- Last updated
- 2020-12-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03251443. Inclusion in this directory is not an endorsement.